Literature DB >> 8695687

[Clinical relevance of gram-negative bacteria having inducible chromosomic beta-lactamase at an intensive care unit].

F Navarro1, C Alonso, J Ballús, E Miró, F March, P Coll, B Mirelis.   

Abstract

BACKGROUND: The aim of the study was to determine the frequency of third-generation cephalosporins and aztreonam resistance in gram-negative bacteria with inducible chromosomal beta-lactamase (beta Lac-ind) after beta-lactam therapy in the medical-surgical intensive care unit (ICU) at a university-affiliated hospital. PATIENTS AND METHODS: We studied 34 infections in 29 patients admitted to the ICU. All were infected by strains with beta Lac-ind and all were treated with beta-lactam antibiotics. Susceptibility was determined by disc-diffusion. The beta-lactamase activity of those strains showing constitutive beta-lactamase overproduction were characterized by isoelectrofocusing. When this derepression occurred during the therapy, the strains were compared by genomic macrorestriction (PGFE).
RESULTS: In 29 out of 34 infections the initial strains was susceptible. In 11 cases, the culture were not negativized in spite of their susceptible pattern. In 4 cases there was derepression during therapy. In 5 cases the initial strains were derepressed. The microorganisms isolated more frequently were Pseudomonas aeruginosa (22 cases) and Enterobacter cloacae (5 cases). The beta-lactamase activity detected correspond well with a betaLac-ind. In those cases with derepression during therapy, the initial susceptible strain and the resistant strain were identical by PGFE.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695687

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  1 in total

1.  Type I beta-lactamases of Enterobacter cloacae and resistance to beta-lactam antibiotics.

Authors:  M T Tejedor-Junco; M González-Martín; P Lupiola; Z González-Lama
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.